Equity
AOCI
Bristol-Myers Squibb AOCI increased by 10.1% to -$1.37B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.8%, from -$1.42B to -$1.37B. Over 5 years (FY 2020 to FY 2025), AOCI shows an upward trend with a -3.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryRisk
SignalContext dependent
VolatilityVolatile
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Fluctuations often signal changes in foreign exchange rates, interest rate environments, or pension funding status.
Detailed definition
Accumulated Other Comprehensive Income (AOCI) captures the cumulative unrealized gains and losses that are excluded from...
Peer comparison
Standard equity component for large multinational corporations with complex balance sheets.
Metric ID:
aociHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$1.52B | -$1.42B | -$1.27B | -$1.23B | -$992.00M | -$841.00M | -$1.28B | -$1.37B | -$1.39B | -$1.29B | -$1.55B | -$1.40B | -$1.46B | -$1.47B | -$1.24B | -$1.42B | -$1.55B | -$1.51B | -$1.52B | -$1.37B |
| QoQ Change | — | +6.2% | +11.0% | +3.1% | +19.3% | +15.2% | -52.3% | -6.8% | -1.4% | +7.3% | -20.2% | +9.4% | -4.0% | -0.8% | +15.7% | -15.0% | -9.1% | +2.6% | -0.7% | +10.1% |
| YoY Change | — | — | — | — | +34.7% | +40.9% | -1.0% | -11.3% | -39.8% | -52.9% | -20.7% | -2.3% | -5.0% | -14.2% | +19.9% | -1.7% | -6.7% | -3.1% | -23.1% | +3.8% |
Range-$1.55B – -$841.00M
CAGR-2.1%
Avg YoY Growth-5.2%
Median YoY Growth-4.0%
AOCI at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's aoci?
- Bristol-Myers Squibb (BMY) reported aoci of -$1.37B in Q1 2026.
- How has Bristol-Myers Squibb's aoci changed year-over-year?
- Bristol-Myers Squibb's aoci increased by 3.8% year-over-year, from -$1.42B to -$1.37B.
- What is the long-term trend for Bristol-Myers Squibb's aoci?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's aoci has grown at a -3.7% compound annual growth rate (CAGR), from -$1.84B to -$1.52B.
- What does aoci mean?
- The cumulative total of unrealized gains and losses not yet reflected in net income.